Skip to main content
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

12.04.2019 | leitlinien für die praxis

Diabetische Neuropathie und diabetischer Fuß (Update 2019)

verfasst von: Monika Lechleitner, Heidemarie Abrahamian, Claudia Francesconi, Markus Kofler, Wolfgang Sturm, Gerd Köhler

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Begriff der diabetischen Neuropathie umfasst Mono- und Polyneuropathieformen, die diabetische Plexopathie, Radikulopathie und die autonome Neuropathie. Die Leitlinienempfehlungen beschreiben die klinischen Symptome und diagnostischen Möglichkeiten, sowie die Therapiemaßnahmen insbesondere bei der schmerzhaften Form der sensomotorischen Neuropathie, einschließlich der komplexen Problematik des diabetischen Fußes.
Vorheriger Artikel Thrombozytenaggregationshemmer (Update 2019)
Nächster Artikel Diabetische Nierenerkrankung (Update 2019)
Literatur
1.
American Diabetes Association. Microvascular complications and foot care. Standards of Medical Care in Diabetes 2018. Diabetes Care. 2018;41(Suppl 1):S105–S18.CrossRef
2.
Ziegler D, Gries FA. Epidemiologie der peripheren diabetischen Neuropathie. Diabetes Stoffwechs. 1992;1:24–8.
3.
Callaghan BC, Cheng HAT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatment. Lancet Neurol. 2012;11:521–34.PubMedPubMedCentralCrossRef
4.
Young MJ, Boulton AJM, Mac IEO, et al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital population. Diabetologia. 1993;36:150–4.PubMedCrossRef
5.
Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Survey S2 and S3. Pain Med. 2009;10:393–400.PubMedCrossRef
6.
Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boultin AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–4.PubMedPubMedCentralCrossRef
7.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.PubMedPubMedCentralCrossRef
8.
Guastella V, Mick G. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy. Diabetes Metab. 2009;35:12–9.PubMedCrossRef
9.
Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.PubMedCrossRef
10.
Dyck PJ, Karnes JL, O’Brien PC, et al. The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164–70.PubMedCrossRef
11.
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester diabetic neuropathy study. Neurology. 1993;43:817–24.PubMedCrossRef
12.
Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complication study. Diabetes. 1989;38:1456–61.PubMedCrossRef
13.
Van de Pollyranse LV, Valk GD, Renders CM, Heine RJ, Eijk JTM. Longitudinal assessment of the development of diabetic polyneuropathies and associated risk factors. Diabet Med. 2003;19:771–9.
14.
Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14.PubMedCrossRef
15.
Sima AA, Sugimoto K. Experimental diabetic neuropathy. An update. Diabetologia. 1999;42:773–88.PubMedCrossRef
16.
Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanism as therapeutic targets. Nat Rev Neurol. 2011;7:573–83.PubMedCrossRef
17.
Yagihashi S, Yamagishi SI, Wada RI, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain. 2001;124:2448–58.PubMedCrossRef
18.
Hoeldike RD, Bryner KD, Van Dyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res. 2011;21:19–28.CrossRef
19.
Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94:2157–63.PubMedPubMedCentralCrossRef
20.
Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep. 2011;3:216–27.
21.
Vinik AI, Maser RE, Mitchell BD, Freema R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79.PubMedCrossRef
22.
Tesfaye S, Vileikyte L, Rayman G, et al. On behalf of the toronto expert panel on diabetic neuropathy. Diabetes Metab Res Rev. 2011;27:629–38.PubMedCrossRef
23.
Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes-Weinstein monofilaments. Phys Ther. 1996;76:68–71.PubMedCrossRef
24.
Meijer JW, Bosma E, Leprandt JD, Links TP, Smit AJ, Stewart RE, Van Der Hoeven JH, Hoogenberg K. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptoms and diabetic neuropathy examination score. Diabetes Care. 2003;26:697–701.PubMedCrossRef
25.
Rahman M, Griffin SJ, Rathman W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-bases comparison of four measures. Diabet Med. 2003;20:368–74.PubMedCrossRef
26.
Zochodne DW. Diabetes mellitus and the peripheral nervous system: Manifestations and mechanisms. Muscle Nerve. 2007;36:144–66.PubMedCrossRef
27.
Feldman EL. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–9.PubMedCrossRef
28.
Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW. Evidence-based guideline: treatment of painful diabetic neuropathy—report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine& Rehabilitation. Muscle Nerve. 2011;43:910–7.PubMedCrossRef
29.
Bolton CF, Remtulla H, Toth B, Bernardi L, Lindsay RM, Maryniak O, Burton SR. Distinctive electrophysiological features of denervated muscle in uremic patients. J Clin Neurophysiol. 1997;14:539–42.PubMedCrossRef
30.
Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, Nolano M, Merkies ISJ, Polydefkis M, Smith AG, Sommer C, Valls-Solé J. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903–912, e44-9.PubMedCrossRef
31.
Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, Boulton AJ. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46:683–8.PubMedCrossRef
32.
Diabetes Control and Complication Trial Research Group.. The effects of intensive treatment of diabetes on the development and progressive of long term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
33.
Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial. Diabetes Care. 2006;29:340–4.PubMedPubMedCentralCrossRef
34.
Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant. 2010;15:119–23.PubMedCrossRef
35.
UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and rate of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;12:837–63.
36.
Holman RR, Paul SK, Bethal MA, et al. 10-years follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–84.PubMedCrossRef
37.
Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients. The Oslo study. Diabetologia. 1994;37:579–84.PubMedCrossRef
38.
Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose levels:the Stockholm Diabetes Intervention Study (SDIS) at 10-years follow up. Diabetologia. 1996;31:1483–8.CrossRef
39.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef
40.
Duckworth W, Abraira C, Moritz T, et al. Intensive glucose control and complications in American Veterans with type 2 diabetes. N Engl J Med. 2009;8:129–39.CrossRef
41.
Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes Care. 2008;31(Suppl 2):255–61.
42.
Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the Nathan 1 trial. Diabetes Care. 2011;34:2054–60.PubMedPubMedCentralCrossRef
43.
McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377–85.PubMedPubMedCentral
44.
Agathos E, Tentolouris A, Eleftheriadou I, KAtsaouni P, Nemtzas I, Petrou A, Papanikolaou C, Tentolouris N. Effect of alpha-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res. 2018;46:1779–90.PubMedPubMedCentralCrossRef
45.
Ziegler D, Fonseca V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J Diabetes Complicat. 2015;29:146–56.PubMedCrossRef
46.
Snedcor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167–84.CrossRef
47.
48.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. J Am Med Assoc. 2005;293:217–28.CrossRef
49.
Jeffcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJM. Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care. 2018;41:645–52.PubMedCrossRef
50.
Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382–7.PubMedCrossRef
51.
Jude EB, Oyibo S, Chalmers N, Boulton AJM. Peripheral arterial disease in diabetic and nondiabetic patients. Diabetes Care. 2001;24:1433–7.PubMedCrossRef
52.
Bakker K, Apelqvist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):225–31.PubMedCrossRef
53.
54.
American Diabetes Association, American Association of Clinical Endocrinologists, Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31:1679–85.CrossRef
55.
European Stroke Organization, Aboyans V, Ricco JB, Bartelink ML, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Soceity for Vascular Surgery (ESVS). Eur Heart J. 2018;39:762–821.
56.
Schaper NC, Andros G, Apelqvist J, Bakker K, Lammer J, Lepantalo M, Mills JL, Reekers J, Shearman CP, Zierler RE, Hinchliffe RJ, et al. Specific guidelines for the diagnosis and treatment of peripheral arterial disease in a patients with diabetes and ulceration of the foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):236–7.PubMedCrossRef
57.
Brandl R, Stiegler H. Das diabetische Fußsyndrom – Pathogenese, Diagnostik, Therapie und Prävention. Dtsch Med Wochenschr. 2015;140:593–602.PubMedCrossRef
58.
Morbach S, Müller E, Reike H, Risse A, Rümenapf G, Spraul M. Diabetic foot syndrome. Exp Clin Endocrinol Diabetes. 2014;122:416–24.PubMedCrossRef
59.
Malecki R, Rosinski K, Adamiec R. Etiological factors of infections in diabetic foot syndrome—attempt to define optimal empirical therapy. Adv Clin Exp Med. 2014;23:39–48.PubMedCrossRef
60.
Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, Löndahl M, Price PE, Jeffcoate WJ. A Systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28(Suppl 1):119–41.PubMedCrossRef
61.
Sanders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. In: Bowker JH, Pfeifer MA, Hrsg. Levin and O’Neals’s. The diabetic foot. 6. Aufl. St. Louis: CV Mosby; 2001. S. 439–66.
62.
Short DJ, Zgonis T. Management of osteomyelitis and bone loss in the diabetic charcot foot and ankle. Clin Podiatr Med Surg. 2017;34:381–7.PubMedCrossRef
Metadaten
Titel
Diabetische Neuropathie und diabetischer Fuß (Update 2019)
verfasst von
Monika Lechleitner
Heidemarie Abrahamian
Claudia Francesconi
Markus Kofler
Wolfgang Sturm
Gerd Köhler
Publikationsdatum
12.04.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-019-1487-4

Weitere Artikel der Sonderheft 1/2019

Geriatrische Aspekte bei Diabetes mellitus (Update 2019)

  • leitlinien für die praxis

Lebensstil: körperliche Aktivität und Training in der Prävention und Therapie des Typ 2 Diabetes mellitus (Update 2019)

  • leitlinien für die praxis

Gestationsdiabetes (GDM) (Update 2019)

  • Open Access
  • leitlinien für die praxis

Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2019)

  • leitlinien für die praxis

Geschlechtsspezifische Aspekte bei Prädiabetes und Diabetes mellitus – klinische Empfehlungen (Update 2019)

  • Open Access
  • leitlinien für die praxis

Migration und Diabetes (Update 2019)

  • leitlinien für die praxis